Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal

May 12, 2026 09:37 AM EDT News Briefing Alk­er­mes' nar­colep­sy Phase 3 suc­cess; Boehringer's an­ti­body deal ENDPOINTS Plus, news from Vista­gen, En­ter­prise Ther­a­peu­tics, Cere­vance and Me­men­to Med­i­cines. 😴 Alk­er­mes’ nar­colep­sy drug suc­ceeds in Phase 3 study: The com­pa­ny’s drug Lum­ryz, ap­proved in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER